image: The leading peer-reviewed scientific journal in contact dermatitis, and the only journal in its field that publishes leading research in atopic, contact, occupational, environmental, and drug dermatitis.
Credit: Mary Ann Liebert, Inc.
The new Contact Allergen Management Program (CAMP) 2.0, from the American Contact Dermatitis Society (ACDS), is a web- and app-based resource designed to help patients manage allergic contact dermatitis. CAMP is a free resource available to ACDS members and their patients.
CAMP offers personalized medicine to manage the symptoms of Allergic Contact Dermatitis by generating safe lists based on individual patch testing results. The tool provides patients with access to product information for thousands of items allowing them to easily identify which products are safe to use.
The much-anticipated release of CAMP 2.0 includes many exciting new features that enhance both the provider and patient experience to save time and improve outcomes.
The streamlined provider interface simplifies the process for creating and updating patient safe lists with an improved allergen search feature, full transparency with cross-reactor groupings, and the ability to automatically include Allergen Information sheets in the patient’s account.
A robust database of over 100,000 products with expanded categories offers patients more safe options to choose from. New interactive tools help patients find their safe products easier by allowing them to make suggestions for new products, rate their experience with products, submit product reports for items that are discontinued or need to be updated, and scan product UPC codes for instant safety feedback.
An increased level of transparency and education helps patients better understand their allergens and why products are safe. CAMP 2.0 expands from the Safe List to include the Unsafe List, a feature that allows patients to understand why a product is unsafe by displaying allergens in the ingredient list in bold red typeface. Patients can learn more about their allergens with automatically included Allergen Information Sheets stored in the Learning Center of their accounts. The Quality-of-Life feature in CAMP 2.0 allows patients to track how their allergic contact dermatitis is affecting their quality of life over time. Recording their scores periodically helps identify their progress.
Learn more about CAMP 2.0 at www.contactderm.org/acds-camp.
About the Journal
Dermatitis® is the leading peer-reviewed scientific journal in contact dermatitis and is the only journal in its field that publishes leading research in atopic, contact, occupational, environmental, and drug dermatitis. International in scope, the journal publishes research related to immunobiology of atopic dermatitis therapy, descriptions of important findings that result from clinical, translational, or basic research related to the mentioned types of dermatitis, epidemiology and population studies, health care disparities, skin of color, and allergy/patch testing in atopic dermatitis. Dermatitis® is the Official Journal of the American Contact Dermatitis Society (ACDS).
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
Journal
Dermatitis
Method of Research
Content analysis
Subject of Research
Not applicable